🇪🇺 Dolobid in European Union

EMA authorised Dolobid on 17 July 2025

Marketing authorisation

EMA — authorised 17 July 2025

  • Application: EMEA/H/C/006248
  • Marketing authorisation holder: Purpose Pharma International AB
  • Local brand name: Attrogy
  • Indication: Attrogy is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy.
  • Status: approved

The European Medicines Agency (EMA) granted marketing authorisation for Attrogy (Dolobid) on 17 July 2025. Attrogy is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv) in adult patients with stage 1 or stage 2 polyneuropathy. This approval allows Purpose Pharma International AB to market Attrogy in the European Union for this specific indication.

Read official source →

Dolobid in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in European Union

Frequently asked questions

Is Dolobid approved in European Union?

Yes. EMA authorised it on 17 July 2025.

Who is the marketing authorisation holder for Dolobid in European Union?

Purpose Pharma International AB holds the EU marketing authorisation.